ArticleInfectious diseases (London, England)2026

Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation.

Amy Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.